<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01231568</url>
  </required_header>
  <id_info>
    <org_study_id>113468</org_study_id>
    <nct_id>NCT01231568</nct_id>
  </id_info>
  <brief_title>An Open Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation Positive Tumor</brief_title>
  <official_title>An Open-Label Study to Examine the Effects of a High-Fat Meal and Particle Size on the Pharmacokinetics of Orally Administered GSK2118436 in Subjects With BRAF Mutation-Positive Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to evaluate the effects of a high fat meal on the pharmacokinetics of&#xD;
      150 mg of GSK2118436, as well as the effects of particle size on the relative bioavailability&#xD;
      of GSK2118436.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      GSK2118436 is an orally administered, potent and selective small molecule BRAF inhibitor that&#xD;
      is currently being developed for the treatment of BRAF mutation-positive tumors. This study&#xD;
      is designed to evaluate the effects of particle size on the relative bioavailability of&#xD;
      GSK2118436 (Cohort 1) and to evaluate the effects of a high-fat meal on the pharmacokinetics&#xD;
      of GSK2118436 (Cohort 2). Subjects will randomly receive two of four possible regimens over&#xD;
      two periods. Subjects enrolled in Cohort 1 will receive a single 150 mg dose of GSK2118436 as&#xD;
      micronized particles fasted (gelatin capsule formulation) and a single 150 mg dose of&#xD;
      GSK2118436 as non-micronized particles fasted (larger particle size). Subjects enrolled in&#xD;
      Cohort 2 will receive a single 150 mg dose of GSK2118436 (HydroxyPropyl Methyl Cellulose&#xD;
      (HPMC) capsule formulation) fasted and with a high-fat breakfast. GSK2118436 will be&#xD;
      administered as the mesylate salt (equivalent to 150 mg free base). Safety and tolerability&#xD;
      will also be evaluated. The study will be conducted at a sufficient number of centers to&#xD;
      complete approximately 28 adult subjects (14 subjects per cohort) with BRAF mutation-positive&#xD;
      tumors. Following completion of this study, subjects may continue dosing with GSK2118436 in&#xD;
      the roll-over study, Protocol BRF114144.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 21, 2010</start_date>
  <completion_date type="Actual">May 13, 2011</completion_date>
  <primary_completion_date type="Actual">May 13, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma-concentration time curve (AUC) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life (t1/2) of GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC, Cmax, Tmax and t1/2 of GSK2118436 metabolites (GSK2285403, GSK2167542 and GSK2298683) and ratio of metabolite to parent drug GSK2118436</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 24, 48, 72 and 96 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with adverse events as a measure of safety and tolerability</measure>
    <time_frame>From date of first dose until transition to rollover protocol BRF114144 (approximately 12 days) or study follow up visit if subject does not transition to BRF114144 (approx 22 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 1 and two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg non-micronized gelatin capsules, dosed fasted (Regimen B) in Period 1 and two 75 mg micronized gelatin capsules, dosed fasted (Regimen A) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 1 and two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive two 75 mg micronized HPMC capsules, dosed with a high-fat meal (Regimen D) in Period 1 and two 75 mg micronized HPMC capsules, dosed fasted (Regimen C) in Period 2. Dosing will occur in the morning of Day 1 in each period, and dosing between periods will be separated by at least one week.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen A</intervention_name>
    <description>Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted</description>
    <arm_group_label>Cohort 1 Treatment Sequence 1</arm_group_label>
    <arm_group_label>Cohort 1 Treatment Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen B</intervention_name>
    <description>Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted</description>
    <arm_group_label>Cohort 1 Treatment Sequence 1</arm_group_label>
    <arm_group_label>Cohort 1 Treatment Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen C</intervention_name>
    <description>Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted</description>
    <arm_group_label>Cohort 2 Treatment Sequence 1</arm_group_label>
    <arm_group_label>Cohort 2 Treatment Sequence 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regimen D</intervention_name>
    <description>Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal</description>
    <arm_group_label>Cohort 2 Treatment Sequence 1</arm_group_label>
    <arm_group_label>Cohort 2 Treatment Sequence 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female at least 18 years of age at the time of signing the informed consent&#xD;
             form;&#xD;
&#xD;
          -  Capable of giving written informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the consent form;&#xD;
&#xD;
          -  Body weight &gt;/= to 45 kg and a Body Mass Index (BMI) &gt;/= to 19 kg/m2 and less than or&#xD;
             equal to 35 kg/m2 (inclusive);&#xD;
&#xD;
          -  Able to swallow and retain oral medication;&#xD;
&#xD;
          -  BRAF mutation-positive tumor as determined via relevant genetic testing;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1 at the time of&#xD;
             transition to this study. NOTE: Subjects with an ECOG performance status of &lt;/= to 2&#xD;
             may be eligible with the approval of the GlaxoSmithKline (GSK) Medical Monitor.&#xD;
&#xD;
          -  Women of child-bearing potential and men with reproductive potential must be willing&#xD;
             to practice acceptable methods of birth control. Additionally, women of child-bearing&#xD;
             potential must have a negative serum pregnancy test within 14 days prior to the first&#xD;
             dose of study treatment;&#xD;
&#xD;
          -  Must have adequate organ function as defined by the following values:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;/= to 1.2 x 10^9/L&#xD;
&#xD;
          -  Hemoglobin &gt;/= to 9 g/dL&#xD;
&#xD;
          -  Platelets &gt;/= to 100 x 10^9/L&#xD;
&#xD;
          -  Serum bilirubin &lt;/= to 1.5 x upper limit of normal (ULN)&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) &lt;/= to 2.5 x ULN;&#xD;
             &lt;5 x ULN if liver metastases are present (with approval of GSK medical monitor)&#xD;
&#xD;
          -  Serum creatinine &lt;/= to ULN or calculated creatinine clearance &gt;/= 60 mL/min&#xD;
&#xD;
          -  Prothrombin time (PT)/International normalized ratio (INR) and partial thromboplastin&#xD;
             time (PTT) &lt; /= to 1.3 x ULN&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;/= to institutional lower limit of normal&#xD;
             by Echocardiogram&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently receiving cancer therapy (e.g., chemotherapy with delayed toxicity,&#xD;
             extensive radiation therapy, immunotherapy, biologic therapy) within the last three&#xD;
             weeks; chemotherapy regimens without delayed toxicity within the last two weeks; or&#xD;
             use of an investigational anti-cancer drug within 28 days preceding the first dose of&#xD;
             GSK2118436;&#xD;
&#xD;
          -  Current use of a prohibited medication or requires any of these medications during the&#xD;
             study;&#xD;
&#xD;
          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice from seven&#xD;
             days prior to the first dose of study medication;&#xD;
&#xD;
          -  Current use of therapeutic warfarin (note: low molecular weight heparin and&#xD;
             prophylactic low-dose warfarin are permitted);&#xD;
&#xD;
          -  History of sensitivity to heparin or heparin-induced thrombocytopenia;&#xD;
&#xD;
          -  Any major surgery within the last four weeks;&#xD;
&#xD;
          -  Unresolved toxicity greater than National Cancer Institute Common Terminology Criteria&#xD;
             for Adverse Events, version 4.0 (NCI CTCAE v4.0) [NCI, 2009] Grade 2 from previous&#xD;
             anti-cancer therapy except alopecia;&#xD;
&#xD;
          -  Presence of active gastrointestinal disease or other condition (e.g., small bowel or&#xD;
             large bowel resection) that will interfere significantly with the absorption of drugs.&#xD;
             If clarification is needed as to whether a condition will significantly affect&#xD;
             absorption of drugs, contact the GSK medical monitor for permission to enroll the&#xD;
             subject;&#xD;
&#xD;
          -  A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or&#xD;
             Hepatitis C Virus (HCV) infection (subjects with laboratory evidence of HBV clearance&#xD;
             may be enrolled with permission of the GSK medical monitor);&#xD;
&#xD;
          -  Presence of invasive malignancy other than one of the malignancies covered under&#xD;
             Inclusion Criterion #5; patients with a history of malignancy that have been&#xD;
             definitively treated can be enrolled with approval of the GSK medical monitor;&#xD;
&#xD;
          -  Subjects with brain metastases are excluded if their brain metastases are either:&#xD;
&#xD;
        Symptomatic Treated (surgery, radiation therapy) but not clinically and radiographically&#xD;
        stable one month after local therapy, or Asymptomatic and untreated but &gt; 1 cm in the&#xD;
        longest dimension Patients with small (â‰¤ 1 cm in the longest dimension), asymptomatic brain&#xD;
        metastases that do not need immediate local therapy can be enrolled with the approval of&#xD;
        the GSK medical monitor. Subjects on a stable dose of corticosteroids for more than one&#xD;
        month, or those who have been off corticosteroids for at least two weeks can be enrolled&#xD;
        with approval of the GSK medical monitor. Subjects must also be off of enzyme-inducing&#xD;
        anticonvulsants for more than four weeks;&#xD;
&#xD;
          -  Presence of rheumatoid arthritis;&#xD;
&#xD;
          -  History of alcohol or drug abuse within six months prior to screening;&#xD;
&#xD;
          -  Corrected QT (QTc) interval &gt;/= to 480 msecs;&#xD;
&#xD;
          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,&#xD;
             or stenting within the past 24 weeks;&#xD;
&#xD;
          -  Class II, III, or IV heart failure as defined by the New York Heart Association (NYHA)&#xD;
             functional classification system; abnormal cardiac valve morphology documented by&#xD;
             echocardiogram (subjects with minimal abnormalities [ie, mild regurgitation/stenosis]&#xD;
             can be entered on study with approval from the GSK medical monitor); or history of&#xD;
             known cardiac arrhythmias (except sinus arrhythmias) within the past 24 weeks;&#xD;
&#xD;
          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs&#xD;
             chemically related to the study drugs, or excipients (note: to date there are no known&#xD;
             drugs chemically related to GSK2118436 which are approved by the Food and Drug&#xD;
             Administration);&#xD;
&#xD;
          -  Uncontrolled medical conditions (e.g., diabetes mellitus, hypertension),&#xD;
             psychological, familial, sociological, or geographical conditions that do not permit&#xD;
             compliance with the protocol; or unwillingness or inability to follow the procedures&#xD;
             required in the protocol;&#xD;
&#xD;
          -  Subjects with known glucose 6 phosphate dehydrogenase (G6PD) deficiency;&#xD;
&#xD;
          -  The subject has participated in a clinical trial and has received an investigational&#xD;
             product within the following time period prior to the first dosing day in the current&#xD;
             study: 30 days, five half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer);&#xD;
&#xD;
          -  Where participation in the study would result in donation of blood or blood products&#xD;
             in excess of 500 mL within a 56 day period;&#xD;
&#xD;
          -  Pregnant females as determined by positive human chorionic gonadotrophin (hCG) test at&#xD;
             screening or prior to dosing;&#xD;
&#xD;
          -  Lactating females who are actively breast feeding;&#xD;
&#xD;
          -  Subject is mentally or legally incapacitated;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <study_first_submitted>October 21, 2010</study_first_submitted>
  <study_first_submitted_qc>October 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2010</study_first_posted>
  <last_update_submitted>November 10, 2017</last_update_submitted>
  <last_update_submitted_qc>November 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>food effect; high fat meal</keyword>
  <keyword>GSK2118436</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>particle size</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>BRAF positive tumor</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

